Kirk Daffner, M.D. and Margaret O’Connor, Ph.D. were featured in the story, “You can no longer drive, and good luck’: Figuring out how long it’s safe to drive has become the third rail of aging.”
Cognitive neurologist sees value in age-focused conversations around Biden’s exit, but also a lack of nuance
Study suggests genetics are a cause, not just a risk for some with Alzheimer’s.
Patients planning to receive anti-amyloid treatments such as lecanemab first must enroll in a registry to help clinicians draw conclusions on the drugs’ safety and efficacy.
Dr. Megan Richie, neurohospitalist at UCSF, spoke to Dr. Seth A. Gale, Co-Director of the Brain Health Program and Assistant Professor of Neurology at Harvard Medical School.
Researchers at the Brigham are developing and advancing treatment options for Alzheimer’s disease by intervening early to prevent the symptoms of the disease, taking aim at new targets, and building on the legacy of the Department of Neurology’s top researchers.